drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
A fully human type I anti-CD20 monoclonal antibody administered subcutaneously that depletes CD20+ B cells via complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity, reducing B-cell antigen presentation and autoantibody production in multiple sclerosis.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Ofatumumab
drug_category
CYTOTOXIC ANTIBODY
drug_class
Cytotoxic protein
drug_delivery_route
Subcutaneous
drug_mechanism_of_action
Fully human type I anti-CD20 monoclonal antibody that binds CD20 on B lymphocytes and depletes them via complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity, reducing B-cell antigen presentation and autoantibody production.
drug_name
Ofatumumab (Kesimpta)
nct_id_drug_ref
NCT06156683